The miR-1906 mimic attenuates bone loss in osteoporosis by down-regulating the TLR4/MyD88/NF‐κB pathway by Xie, H. et al.
The miR-1906 mimic attenuates bone loss in
osteoporosis by down-regulating the
TLR4/MyD88/NF-kB pathway
H. XIE, L. CAO, L. YE, G. SHAN and W. SONG
p
Department of Rehabilitation, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China
Received: March 12, 2020 • Accepted: June 12, 2020
Published online: January 06, 2021
© 2020 Akademiai Kiado, Budapest
ABSTRACT
In this study, the ability of microRNA-1906 (miR-1906) to attenuate bone loss in osteoporosis was
evaluated by measuring the effects of a miR-1906 mimic and inhibitor on the cellular toxicity and cell
viability of MC3T3-E1 cells. Bone marrow-derived macrophage (BMM) cells were isolated from female
mice, and tartrate-resistant acid phosphatase signalling was performed in miR-1906 mimic-treated, re-
ceptor-activated nuclear factor kappa-B (NF-kB) ligand (RANKL)-induced osteoclasts. In-vivo, osteo-
porosis was induced by ovariectomy (OVX). Rats were treated with 500 nmol/kg of the miR-1906 mimic
via intrathecal administration for 10 consecutive days following surgery. The effect of the miR-1906
mimic on bone mineral density (BMD) in OVX rats was observed in the whole body, lumbar vertebrae
and femur. Levels of biochemical parameters and cytokines in the serum of miR-1906 mimic-treated
OVX rats were analysed. The mRNA expression of toll-like receptor 4 (TLR4), myeloid differentiation
primary response 88 (MyD88), p-38 and NF-kB in tibias of osteoporotic rats (induced by ovariectomy)
was observed using quantitative reverse-transcription polymerase chain reaction. Treatment with the
miR-1906 mimic reduced cellular toxicity and enhanced the cell viability of MC3T3-E1 cells. Further-
more, osteoclastogenesis in miR-1906 mimic-treated, RANKL-induced osteoclast cells was reduced,
whereas the BMD in the miR-1906 mimic-treated group was higher than in the OVX group of rats.
Treatment with the miR-1906 mimic also increased levels of biochemical parameters and cytokines in the
serum of ovariectomised rats. Finally, mRNA expression levels of TLR4, MyD88, p-38 and NF-kB were
lower in the tibias of miR-1906 mimic-treated rats than in those of OVX rats. In conclusion, the miR-
1906 mimic reduces bone loss in rats with ovariectomy-induced osteoporosis by regulating the TLR4/
MyD88/NF-kB pathway.
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INTRODUCTION
Osteoporosis is a bone disease that involves reduced bone density and strength, which, in turn,
increases an individual’s risk of suffering bone fractures [1]. Osteoporosis is caused by an
imbalance between bone resorption and formation. Several factors can contribute to this
imbalance, including oestrogen deficiency [2]. Oestrogen deficiency is one reason why the global
prevalence of osteoporosis is higher in postmenopausal women [3].
Oestrogen deficiency contributes to the development of osteoporosis because it increases
cytokine levels and the activity of the immune system, which can increase osteoclast activity in
the body [4]. By altering the activity of osteoclasts and osteoblasts, oestrogen deficiency makes
bones more fragile by promoting their remodelling [5]. Current literature suggests that it is the
alteration of the toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor
kappa B (TLR4/MyD88/NF-kB) pathway that causes the induction of bone remodelling under
oestrogen-deficient conditions [6], and that monkey TLR4 increases cytokine levels, which
contributes to the development of an inflammatory response that includes osteoporosis [7].
Oestrogen deficiency also increases oxidative stress levels, which can likewise result in the above-
mentioned activity [8].
Although several drugs can help manage osteoporosis, including hormone replacement
therapy, they are associated with certain risks, including cardiovascular risks and the risk of
developing endometrial cancer [8]. Therefore, a new therapeutic approach is needed to manage
osteoporosis.
Small and non-coding RNAs, known as microRNAs (miRs) are involved in the development
and progression of osteoporosis. They can also alter the activity of osteoclasts and osteoblasts
[9]. Several clinical and pre-clinical studies found that miRs alter the bone remodelling process
by affecting bone resorption, osteoclastogenic activity and bone formation. Furthermore, a miR-
1906 mimic was found to enhance neuronal cells and reduce neuropathic pain by regulating the
TLR-4/NF-kB pathway [10]. It was also found to be involved in the management of cerebral
stroke [11]. Considering the involvement of miR-1906 in these processes, the ability of miR-
1906 to attenuate bone loss in osteoporosis was evaluated in this study.
MATERIAL AND METHODS
Cell line and culture
MC3T3-E1 cells were procured from Peking Union Medical College in Beijing, China, and
incubated in penicillin (100 U/mL), streptomycin (100 U/mL) and 10% foetal bovine serum
(FBS) supplemented with Dulbecco’s modified Eagle medium at 37 8C. The tibias and femurs of
C57BL/6J mice were used to extract bone marrow cells. Additional bone marrow-derived
macrophages were generated by incubating the isolated cells for 3 days in penicillin (100 U/mL),
streptomycin (100 U/mL) and 10% FBS supplemented with a-modified Eagle medium. MC3T3-
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E1 cells were then transfected with a miR-1906 mimic or inhibitor for 2 days using Lipofect-
amine 2000 to promote or inhibit the expression of miR-1906.
Chemicals. The miR-1906 mimic and miR-1906 inhibitor were purchased from Sigma Aldrich
(St. Louis, MO, USA). Enzyme-linked immunosorbent assay (ELISA) kits were purchased from
R&D Systems (Minneapolis, MN, USA). Primers used for quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) were obtained from Thermo Fisher Scientific (Wil-
mington, DE, USA).
Cell-Counting Kit-8 (CCK-8) assay. MC3T3-E1 cells (53 103 cells/well) were seeded into 12-
well plates. Each well was treated with 10ml of CCK-8 reagent and incubated for 2 h. Amicroplate
reader was used to determine the absorbance at a wavelength of 450 nm. A lactate dehydrogenase
(LDH) assay kit was used to estimate cellular toxicity according to the manufacturer’s protocol.
Tartrate-resistant acid phosphatase (TRAP) staining
Bone marrow-derived macrophages (BMMs) (13 105 cells/mL) were seeded into a 12-well plate
and treated with 100 ng/mL of the RANKL and 50 ng/mL macrophage colony-stimulating factor
(M-CSF) for 4 days. The cells were then treated with the miR-1906 mimic on different days,
such as days 1, 2 and 3. Cells were fixed on day 4 and stained with tartrate-resistant acid
phosphatase (TRAP). An inverted microscope was used to record images.
Animals. Thirty female Sprague–Dawley rats weighing 300–320 g were kept under a 12-h light/
12-h dark cycle (humidity, 60 ± 5%; temperature, 24 ± 38C). The protocols used in the animal
experiments were approved by the Institutional Animal Ethical Committee of Capital Medical
University, Beijing, China (IAEC/CMU/2019/08).
Induction of osteoporosis and treatment. Bilateral ovariectomies were performed in accordance
with a previously reported study [12]. All animals were anaesthetised. An incision of approxi-
mately 2 cm was made on the abdomen of each animal. Ovaries were exposed using artery
forceps. Bilateral ovaries were removed in each animal, the abdominal fat pad was repositioned
and sutures were used to close the wound. Animals in the control group were subjected to the
same surgery, but without removal of the ovaries.
The miR-1906 mimic was purchased from Sigma Aldrich (catalogue no. MLMIR0883) and
delivered using theMaxSuppressor In Vivo RNA-LANCEr II RNA delivery system in accordance
with the manufacturer’s protocol. All animals were separated into three different groups  a
control group, an OVX (ovariectomy) group and a miR-1906 mimic group. The miR-1906
mimic group received 500 nmol/kg of the mimic intrathecally for 10 consecutive days following
surgery.
Bone mineral density (BMD) measurement. Dual energy X-ray absorptiometry was used to
determine the BMD in animals. A Zoletil-Rompun mixture was used to anaesthetise the ani-
mals, and scans of the femur, lumbar vertebrae and whole body were used to calculate BMD.
Determination of biochemical parameters. All animals were anaesthetised, and blood was
withdrawn from the retro orbital plexuses of the rats. The blood was centrifuged at 2,000 RPM
for 10 min to separate the serum. Levels of osteocalcin (OC), C-telopeptide of type 1 collagen
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(CTX), bone-specific alkaline phosphatase (BSAP), interleukin (IL)-1b, tumour necrosis factor
(TNF)-a and IL-6 were measured in the serum of ovariectomised rats using ELISA in accor-
dance with the manufacturer’s protocol.
Histopathological analysis. The tibias were isolated from each animal, fixed in 10% formalin
solution and stored at a temperature of 40 8C for 2 days. Ethylene diamine tetra acetic acid (10%)
was used to decalcify the tibias. Each tibia was then embedded in liquid paraffin to prepare the wax
blocks. Tibial tissue sections of 4-mm thickness were prepared using a microtome. Haematoxylin
and eosin (H&E) staining was used to stain sections, and a leucocyte acid phosphatase assay kit
was used to determine TRAP activity in osteoclasts according to the manufacturer’s protocol.
qRT-PCR. TRIzol reagent was used to isolate the total RNA from tibial tissues according to the
manufacturer’s protocol. A reverse-transcription kit was used to reverse transcribe cDNA from
RNA according to the manufacturer’s protocol. The ABI Prism 7500 system was then used to
analyse samples treated with the SYBR green/fluorescein qPCR Master Mix kit. The conditions
were as follows: 50 8C for 2 min; 95 8C for 10 min; and 40 cycles of 95 8C for 30 s and 608C for 30
s. The resulting data were analysed using the comparative Ct method. Primers used in this study
are listed below:
Statistical analysis
All data are expressed as the means ± standard error of the mean (n5 10). Data were compared
using a one-way analysis of variance. Post hoc comparisons were made using Dunnett’s test with
GraphPad Prism software (ver. 6.1; GraphPad Software, San Diego, CA, USA). In all analyses,
P < 0.05 was considered to denote statistical significance.
RESULTS
Effects of miR-1906 on cell viability and toxicity
The effects of the miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of
MC3T3-E1 cells are shown in Fig. 1. Treatment with the miR-1906 mimic enhanced cell viability
compared to the control group, whereas treatment with miR-1906 inhibitor decreased the
viability of MC3T3-E1 cells compared to the control group.
TLR4 Forward 59-GCC GGA AAG TTA TTG TGG TGG T-39
Reverse 59-ATG GGT TTT AGG CGC AGA GTT T-39
MyD88 Forward 59-CAA CCA GCA GAA ACA GGA GTC T-39
Reverse 59-ATT GGG GCA GTA GCA GAT GAA G-39
NF-kB Forward 59-GCG CAT CCA GAC CAA CAA TAA C-39
Reverse 59-GCC GAA GCT GCA TGG ACA CT-39
p-38 Forward 59-GAGCGTTACCAGAACCTGTCTC-39
Reverse 59-AGTAACCGCAGTTCTCTGTAGGT-39
b-actin Forward 59-GCC ATG TAC GTA GCC ATC CA-39
Reverse 59-GAA CCG CTC ATT GCC GAT AG-39
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The effects of the miR-1906 mimic and inhibitor on cellular toxicity were estimated by
comparing the level of LDH in treated samples to that in the control group. There was less LDH
in the miR-1906 mimic-treated group than in the control group. However, the miR-1906 in-
hibitor increased the LDH level in MC3T3-E1 cells compared to the control group. These results
show that the miR-1906 mimic increased the proliferation of osteoblasts and reduced the activity
of LDH.
Effect of miR-1906 on RANKL-induced osteoclast differentiation. The effects of the miR-1906
mimic were observed on a number of TRAP-positive multinucleated osteoclasts and RANKL-
induced osteoclasts in BMM-isolated cells. Treatment with the miR-1906 mimic significantly
inhibited osteoclastogenesis. The effect was observed for 3 days. In the miR-1906 mimic group,
osteoclastogenesis was inhibited successively for all 3 days of treatment (Fig. 2). Treatment with
the miR-1906 mimic reduced the differentiation of osteoclasts and thereby inhibited osteo-
clastogenesis in osteoclasts with RANKL-induced activation of RANK.
Effect of miR-1906 mimic on bone mineral density. BMD was measured in the whole body,
lumbar vertebrae and femurs of miR-1906 mimic-treated osteoporotic rats (Fig. 3). BMD was
Fig. 1. Effects of the miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of MC3T3-E1
cells. The Cell-counting Kit-8 assay and lactate dehydrogenase (LDH) assays were used to measure cell
viability and LDH levels in MC3T3-E1 cells, respectively. Data are represented as the means ± standard
error of the mean (SEM; n 5 10); ##P < 0.01 compared to control; ppP < 0.01 compared to miR-1906 mimic
Fig. 2. Effects of the miR-1906 mimic on receptor-activated nuclear factor kappa-B ligand-induced oste-
oclasts in bone marrow-derived macrophage-isolated cells as visualised using TRAP staining
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Fig. 3. Effects of the miR-1906 mimic on bone mineral density (BMD) in the whole body, lumbar vertebrae
and femurs of rats with ovariectomy-induced osteoporosis (OVX). Dual energy X-ray absorptiometry was
used to measure BMD in samples. Data are represented as the means ± SEM (n5 10); ##P < 0.01 compared
to control group; ppP < 0.01 compared to OVX group
Table 1. The miR-1906 mimic enhances osteocalcin (OC), C-telopeptide of type 1 collagen (CTX),
procollagen type I N-terminal propeptide (PINP) and bone-specific alkaline phosphatase (BSAP) levels in
the serum of rats with osteoporosis induced by ovariectomy (OVX)
Sr. No. Group OC (pg/mL) CTX (ng/mL) PINP (ng/mL) BSAP (U/L)
1. Control 9.54 ± 0.62 36.24 ± 2.1 5.92 ± 0.65 8.27 ± 0.41
2. OVX 3.16 ± 0.24## 146 ± 8.06## 24.16 ± 2.34## 14.28 ± 0.56##








Data are represented as the means ± standard error of the mean (SEM; n 5 10); ##P < 0.01 compared to
control group; ppP < 0.01 compared to OVX group.
Fig. 4. Effects of the miR-1906 mimic on inflammatory mediators in the serum of osteoporotic rats.
Enzyme-linked immunosorbent assay was used to measure levels of inflammatory mediators. Data are
represented as the means ± SEM (n 5 10); ##P < 0.01 compared to control group; ppP < 0.01 compared to
OVX group
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lower in the whole body, lumbar vertebrae and femurs of the OVX rats compared to the control
rats. However, BMD increased following treatment with the miR-1906 mimic in osteoporotic
rats. BMD was higher in the whole body, lumbar vertebrae and femurs of miR-1906 mimic-
treated osteoporotic rats, which suggests that treatment with a miR-1906 mimic prevents
osteoporosis.
Effect of miR-1906 mimic on biochemical parameters. The effects of the miR-1906 mimic were
observed by analysing the OC, CTX, procollagen type I N-terminal propeptide (PINP) and
BSAP levels in the serum of osteoporotic rats. Serum CTX and PINP levels were higher in the
OVX group compared to the control group. However, the serum OC level was lower in the OVX
Fig. 5. Effects of the miR-1906 mimic on the tibial tissue of rats with osteoporosis induced by ovariectomy.
(A) Haematoxylin and eosin staining of tibial tissue section. (B) The percentage of TRAP-stained positive
cells in the section of tibial tissue was calculated using a leucocyte acid phosphatase assay kit. Data are
represented as the means ± SEM (n 5 10); ##P < 0.01 compared to control group; ppP < 0.01 compared to
OVX group
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group than in the control group. Furthermore, serum BSAP activity was higher in the OVX
group than in the control group. Treatment with the miR-1906 mimic changed the levels of OC,
CTX, PINP and BSAP in the serum of osteoporotic rats (Table 1). The altered levels of the
biochemical parameters suggest that treatment with the miR-1906 mimic protects against
osteoporosis.
The miR-1906 mimic attenuates inflammatory mediators. The levels of inflammatory medi-
ators were measured in the serum of miR-1906 mimic-treated osteoporotic rats. The serum
levels of IL-1b, IL-6 and TNF-a were significantly enhanced in the OVX group compared to the
control group. There were less inflammatory cytokines in the serum of miR-1906 mimic-treated
rats compared to OVX rats (Fig. 4).
The miR-1906 mimic ameliorates bone resorption. The effect of miR-1906 mimic treatment on
bone resorption was examined via histopathological analysis of the tibial tissue of osteoporotic
rats using H&E and TRAP staining (Fig. 5A and B). In the OVX group, metaplasia of tibia cells
with cancellous bone was observed. In addition, the bone marrow space was larger compared to
that in rats in the control group. Treatment with the miR-1906 mimic reversed the altered
pathophysiology of tibial tissue in osteoporotic rats (Fig. 5A). Furthermore, the number of
TRAP-positive multinucleated osteoclasts was higher in the bone tissue of rats in the OVX
group than in the control group. There were also fewer TRAP-positive multinucleated osteo-
clasts in the tibial tissue of rats treated with the miR-1906 mimic than in the tissue of rats in the
OVX group (Fig. 5B).
The miR-1906 mimic ameliorates the mRNA expression of TLR4, MyD88, p-38 and NF-kB
proteins. The mRNA expression of TLR4, MyD88, p-38 and NF-kB was estimated in the
tibial tissues of miR-1906 mimic-treated osteoporotic rats (Fig. 6). There was an increase in
the mRNA expression of TLR4, MyD88, p-38 and NF-kB in the tibial tissue of rats in the
OVX group compared to rats in the control group. Treatment with the miR-1906 mimic
lowered the mRNA expression of TLR4, MyD88, p-38 and NF-kB in the tibial tissue of
osteoporotic rats.
Fig. 6. Effects of the miR-1906 mimic on the mRNA expression of TLR4, MyD88, p-38 and NF-kB in the
tibias of osteoporotic rats. Levels of mRNA expression were measured using quantitative reverse-tran-
scription polymerase chain reaction. Data are represented as the means ± SEM (n 5 10); ##P < 0.01
compared to control group; ppP < 0.01 compared to OVX group
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DISCUSSION
Osteoporosis, a bone mass disorder, commonly occurs in women following menopause and
increases the chances of developing bone fractures [13]. Conventional drugs available for the
management of osteoporosis have significant limitations. Therefore, there is a need to develop
new therapy to help manage osteoporosis.
In this study, the ability of amiR-1906mimic to attenuate bone loss in an osteoporotic ratmodel
induced by ovariectomy was evaluated. The effects of the miR-1906 mimic and inhibitor on the
cellular toxicity and cell viability of MC3T3-E1 cells were investigated. BMM cells were isolated
from female mice, and TRAP signalling was performed in miR-1906 mimic-treated, RANKL-
induced osteoclasts. BMD was estimated in the whole body, lumbar vertebrae and femurs of miR-
1906mimic-treatedOVXrats. Levels of biochemical parameters and cytokineswere analysed in the
serum of miR-1906-mimic-treated OVX rats. The mRNA expression of TLR4, MyD88, p-38 and
NF-kB in the tibias of the osteoporotic rats was analysed using qRT-PCR.
The effects of miR-1906 on cellular toxicity and viability were also observed in pre-osteoblast
cells—the MC3T3-E1 cells. Treatment with the miR-1906 mimic enhanced cell viability, and cell
toxicity was less pronounced compared to the control cells. The activity, survival and differ-
entiation of osteoclasts are regulated by cytokines such as M-CSF and RANKL, which are
expressed by osteoblast cells [14]. In this study, treatment with a miR-1906 mimic reduced
osteoclastogenesis in RANKL-induced osteoclasts derived from BMM cells.
There are several biomarkers of bone formation and resorption, including the activities of
CTX, OC, BSAP and PINP [15]. Treatments used for the management of osteoporosis attenuate
the altered levels of these biomarkers. Likewise, treatment with a miR-1906 mimic attenuated
altered levels of CTX, OC, BSAP and PINP in the serum of ovariectomised rats. Inflammatory
cytokines have also been reported to regulate bone resorption. Furthermore, a deficiency of
oestrogen results in an increase in the level of inflammatory cytokines [16]. According to the
findings of this study, miR-1906 mimic treatment reduced the levels of inflammatory cytokines
significantly (P < 0.01) compared to levels in the OVX group.
TLR4 activation is also involved in several other pathological conditions such as weight gain,
insulin resistance, inflammation and osteoclastogenesis [7]. One study suggests that TLR4
expression increases in the brain tissue of rats with osteoporosis induced by ovariectomy [17].
The data from this study support those findings. MyD88 signalling also contributes to the
proliferation and development of osteoblasts [18]. Bone resorption and formation activities were
reported to be lower in MyD88–/– mice [19]. Treatment with a miR-1906 mimic ameliorated the
altered expression of MyD88 and TLR4 in the tibial tissue of osteoporotic rats.
CONCLUSION
In conclusion, miR-1906 mimic reduced osteoclastogenesis/bone resorption in a rat model of
osteoporosis induced by ovariectomy via regulation of the TLR4/MyD88/NF-kB pathway. Ul-
timately, treatment with a miR-1906 mimic attenuates bone loss in osteoporosis.
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